Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 26;14(15):3638.
doi: 10.3390/cancers14153638.

The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer-A Practical Clinical Review

Anna Rebecca Lisney  1 , Conrad Leitsmann  2 , Arne Strauß  2 , Birgit Meller  1 , Jan Alexander Bucerius  1 , Carsten-Oliver Sahlmann  1
Affiliations
Review

The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer-A Practical Clinical Review

Anna Rebecca Lisney et al. Cancers (Basel). .

Abstract

The importance of PSMA PET/CT in both primary diagnostics and prostate cancer recurrence has grown steadily since its introduction more than a decade ago. Over the past years, a vast amount of data have been published on the diagnostic accuracy and the impact of PSMA PET/CT on patient management. Nevertheless, a large heterogeneity between studies has made reaching a consensus difficult; this review aims to provide a comprehensive clinical review of the available scientific literature, covering the currently known data on physiological and pathological PSMA expression, influencing factors, the differences and pitfalls of various tracers, as well as the clinical implications in initial TNM-staging and in the situation of biochemical recurrence. This review has the objective of providing a practical clinical overview of the advantages and disadvantages of the examination in various clinical situations and the body of knowledge available, as well as open questions still requiring further research.

Keywords: PET; PET/CT; PSMA; PSMA PET/CT; prostate cancer; prostate-specific membrane antigen.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
MIP of a physiological biodistribution of PSMA PET/CT in a patient after radical prostatectomy, with [68Ga]Ga-PSMA-11; arrows point to physiological uptake in lacrimal glands (1), parotid glands (2), submandibular glands (3), liver (4), spleen (5), kidney (6), duodenum (7), small intestines (8), and unspecific radioactivity in the bladder (9).
Figure 2
Figure 2
MIPs of a typical biodistribution of PSMA PET/CT studies of a patient with metastatic prostate cancer, with [68Ga]Ga-PSMA-11 in 2019 (A) and with [18F]-PSMA-1007 in 2018 (B); arrows point to significant differences in uptake.
See this image and copyright information in PMC

References

    1. Center M.M., Jemal A., Lortet-Tieulent J., Ward E., Ferlay J., Brawley O., Bray F. International Variation in Prostate Cancer Incidence and Mortality Rates. Eur. Urol. 2012;61:1079–1092. doi: 10.1016/j.eururo.2012.02.054. - DOI - PubMed
    1. Kahn D., Williams R.D., Seldin D.W., Libertino J.A., Hirschhorn M., Dreicer R., Weiner G.J., Bushnell D., Gulfo J. Radioimmunoscintigraphy with 111 Indium Labeled Cyt-356 for the Detection of Occult Prostate Cancer Recurrence. J. Urol. 1994;152:1490–1495. doi: 10.1016/S0022-5347(17)32453-9. - DOI - PubMed
    1. Smith-Jones P.M., Vallabahajosula S., Goldsmith S.J., Navarro V., Hunter C.J., Bastidas D., Bander N.H. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237–5243. - PubMed
    1. Maresca K.P., Hillier S.M., Femia F.J., Keith D., Barone C., Joyal J.L., Zimmerman C.N., Kozikowski A.P., Barrett J.A., Eckelman W.C., et al. A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer. J. Med. Chem. 2009;52:347–357. doi: 10.1021/jm800994j. - DOI - PubMed
    1. Hillier S.M., Maresca K.P., Femia F.J., Marquis J.C., Foss C.A., Nguyen N., Zimmerman C.N., Barrett J.A., Eckelman W.C., Pomper M.G., et al. Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer. Cancer Res. 2009;69:6932–6940. doi: 10.1158/0008-5472.CAN-09-1682. - DOI - PMC - PubMed

LinkOut - more resources